Pakistan
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 5.63 (4.44 - 7.31) | 2015 | Modelled | WHO |
| 2.1 (2 - 3.30) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 2.76 (2.73 - 2.79) | 2013 | Modelled | Schweitzer et al, 2015 |
| 2.5 | 2010 | Survey/reported | Qureshi et al, 2010 |
| 2.3 (2.04 - 2.61) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 2.52 (2.23 - 2.85) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.55 (2.24 - 2.89) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.71 (2.39 - 3.05) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.86 (2.53 - 3.22) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.83 (2.53 - 3.14) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.77 (2.49 - 3.05) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.69 (2.45 - 2.95) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.62 (2.40 - 2.85) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.57 (2.37 - 2.79) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.56 (2.36 - 2.78) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.58 (2.39 - 2.79) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.62 (2.43 - 2.83) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.67 (2.47 - 2.88) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.7 (2.50 - 2.91) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.73 (2.53 - 2.95) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.8 (2.59 - 3.04) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.89 (2.65 - 3.14) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.97 (2.71 - 3.25) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.03 (2.76 - 3.32) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.12 (2.84 - 3.42) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.25 (2.95 - 3.58) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.41 (3.08 - 3.76) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.56 (3.19 - 3.92) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.66 (3.29 - 4.05) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.73 (3.33 - 4.16) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.8 (3.36 - 4.26) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.85 (3.38 - 4.35) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.9 (3.38 - 4.45) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.92 (3.35 - 4.55) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.52 (2.23 - 2.83) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.75 (2.02 - 3.67) | 2015 | Modelled | WHO |
| 0.54 (0.43 - 0.68) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.63 (0.50 - 0.79) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.66 (0.52 - 0.82) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.7 (0.55 - 0.86) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.74 (0.60 - 0.91) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.78 (0.63 - 0.96) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.79 (0.64 - 0.96) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.8 (0.65 - 0.96) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.8 (0.66 - 0.96) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.8 (0.66 - 0.95) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.81 (0.67 - 0.95) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.81 (0.67 - 0.95) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.81 (0.67 - 0.95) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.81 (0.67 - 0.96) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.82 (0.68 - 0.96) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.83 (0.69 - 0.98) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.97 (0.81 - 1.14) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.26 (1.04 - 1.49) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.61 (1.33 - 1.91) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.93 (1.59 - 2.29) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.12 (1.75 - 2.52) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.21 (1.83 - 2.63) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.3 (1.89 - 2.74) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.37 (1.96 - 2.84) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.43 (1.99 - 2.92) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.47 (2.01 - 2.99) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.5 (2.02 - 3.04) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.53 (2.03 - 3.09) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.55 (2.04 - 3.14) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.57 (2.04 - 3.20) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.57 (2.01 - 3.26) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.91 (0.79 - 1.04) | 2020 | Modelled | WHO |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 3,962,000 (3,906,000 - 6,364,000) | 2016 | Modelled | Razavi-Shearer et al, 2018 |
| 5,161,400 (4,570,900 - 5,838,200) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 5,363,750 (4,755,000 - 6,038,170) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,263,860 (4,668,650 - 5,946,140) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,212,530 (4,575,290 - 5,916,670) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,420,940 (4,787,850 - 6,093,410) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,579,400 (4,936,260 - 6,265,730) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,408,230 (4,829,360 - 6,008,290) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 5,173,940 (4,665,950 - 5,690,620) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,919,100 (4,483,600 - 5,399,620) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,680,860 (4,305,390 - 5,107,760) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,492,900 (4,134,790 - 4,888,110) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,377,400 (4,043,160 - 4,744,960) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,316,620 (4,000,570 - 4,662,700) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,282,450 (3,974,150 - 4,616,560) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,249,100 (3,950,680 - 4,577,180) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,194,770 (3,892,800 - 4,515,980) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,155,880 (3,848,980 - 4,485,980) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,162,690 (3,841,520 - 4,509,340) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,187,640 (3,850,620 - 4,552,820) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,204,290 (3,839,350 - 4,588,300) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,188,740 (3,814,630 - 4,590,090) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,201,480 (3,820,710 - 4,609,920) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,284,270 (3,892,510 - 4,701,020) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,390,970 (3,972,380 - 4,830,490) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,479,010 (4,028,740 - 4,935,800) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,509,680 (4,034,130 - 4,984,660) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,496,600 (3,997,820 - 5,002,380) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,474,850 (3,947,330 - 5,009,740) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,440,780 (3,893,790 - 5,005,930) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,391,310 (3,802,880 - 5,021,410) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,323,500 (3,696,180 - 5,002,780) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 7.23 (5.30 - 9.67) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 8.56 (5.41 - 12.17) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.57 (5.48 - 12.12) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.59 (5.59 - 11.83) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.57 (5.64 - 11.61) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.6 (5.87 - 11.56) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.69 (6.06 - 11.54) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.67 (6.06 - 11.22) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.6 (6.19 - 11.04) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.46 (6.19 - 10.80) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.39 (6.17 - 10.68) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.27 (6.17 - 10.45) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.4 (6.13 - 10.83) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.37 (6.22 - 10.56) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.13 (6.11 - 10.20) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.89 (6.04 - 9.93) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8 (6.05 - 10.01) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.79 (5.83 - 9.85) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.7 (5.73 - 9.85) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.67 (5.75 - 9.81) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.63 (5.58 - 9.82) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.57 (5.54 - 9.79) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.48 (5.35 - 9.72) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.4 (5.50 - 9.68) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.38 (5.43 - 9.64) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.33 (5.45 - 9.62) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.25 (5.28 - 9.58) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.26 (5.25 - 9.54) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.3 (5.27 - 9.76) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.26 (5.25 - 9.75) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.23 (5.30 - 9.67) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 15,531 | 2016 | Modelled | WHO |
| 9,657 (6,100 - 13,729) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9,894 (6,329 - 13,986) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10,135 (6,599 - 13,963) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10,342 (6,811 - 14,010) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10,973 (7,655 - 14,565) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,202 (7,830 - 14,491) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10,612 (7,238 - 14,262) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,372 (8,182 - 14,594) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,459 (8,383 - 14,627) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,638 (8,562 - 14,813) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,948 (8,715 - 15,402) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,370 (9,232 - 15,624) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,201 (9,063 - 15,388) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,583 (9,524 - 15,756) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,465 (9,378 - 15,639) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,732 (9,747 - 16,025) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,898 (9,656 - 16,298) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,074 (9,734 - 16,719) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,622 (9,966 - 17,526) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,359 (10,008 - 17,093) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,860 (10,135 - 17,916) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,023 (10,034 - 18,218) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,209 (10,556 - 18,591) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,515 (10,671 - 18,946) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,249 (11,104 - 20,149) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,927 (10,797 - 19,620) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,749 (10,970 - 19,338) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,686 (11,324 - 20,956) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,916 (11,508 - 21,399) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16,208 (11,878 - 21,656) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16,208 (11,878 - 21,656) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 75 | 2019 | Survey/reported | WHO/UNICEF |
| 77 | 2020 | Survey/reported | WHO/UNICEF |
| 83 | 2021 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 18 (16 - 21) | 2015 | Survey/reported | Larney et al, 2017 |
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2015 | Survey/reported | NACP, 2015. |
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Eligible for HBV generic medicines
Year of birth dose introduction
2016
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 3.8 (2.80 - 3.90) | 2015 | Modelled | Blach et al, 2017 |
| 5.8 (1.40 - 8.70) | 2014 | Modelled | Gower et al, 2014 |
| 1.78 (1.42 - 2.21) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.78 (1.43 - 2.20) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.79 (1.43 - 2.21) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.02 (1.62 - 2.49) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.3 (1.85 - 2.84) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.41 (1.94 - 2.98) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.5 (2.02 - 3.09) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.57 (2.08 - 3.18) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.62 (2.11 - 3.23) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.63 (2.12 - 3.26) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.63 (2.12 - 3.24) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.61 (2.11 - 3.22) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.6 (2.09 - 3.20) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.58 (2.09 - 3.19) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.57 (2.07 - 3.16) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.5 (2.02 - 3.09) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.37 (1.91 - 2.93) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.22 (1.79 - 2.75) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.1 (1.69 - 2.59) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.05 (1.65 - 2.53) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.06 (1.66 - 2.54) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.09 (1.68 - 2.56) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.12 (1.71 - 2.61) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.16 (1.73 - 2.65) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.18 (1.75 - 2.68) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.18 (1.75 - 2.68) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.17 (1.75 - 2.68) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.16 (1.73 - 2.67) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.13 (1.71 - 2.66) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.1 (1.68 - 2.63) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.68 (1.34 - 2.09) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 4.09 (3.06 - 4.27) | 2019 | Modelled | Dugan et al., 2021 |
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 6.7 (1.60 - 10) | 2014 | Modelled | Gower et al, 2014 |
| 4.8 | 2010 | Survey/reported | Qureshi et al, 2010 |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 36.5 (0 - 79.10) | 2013 | Modelled | Degenhardt L et al, 2017 |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 7,172,000 (5,363,000 - 7,487,000) | 2015 | Modelled | Blach et al, 2017 |
| 2,315,320 (1,854,900 - 2,899,710) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,403,620 (1,929,160 - 2,999,070) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,484,960 (1,991,470 - 3,084,730) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,558,500 (2,057,480 - 3,164,100) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,623,790 (2,106,000 - 3,228,000) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,680,230 (2,143,650 - 3,301,320) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,717,980 (2,182,430 - 3,346,810) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,736,500 (2,201,320 - 3,368,090) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,750,040 (2,215,590 - 3,380,780) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,774,480 (2,232,440 - 3,420,190) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,826,620 (2,279,400 - 3,490,010) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,970,320 (2,394,170 - 3,664,170) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,221,090 (2,594,740 - 3,958,980) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,519,890 (2,837,810 - 4,338,260) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,801,680 (3,069,870 - 4,688,320) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,993,360 (3,223,580 - 4,901,160) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,115,700 (3,324,020 - 5,060,570) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,240,740 (3,422,690 - 5,224,430) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,365,460 (3,516,140 - 5,378,220) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,487,790 (3,612,400 - 5,550,220) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,605,460 (3,700,900 - 5,700,080) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,687,700 (3,773,350 - 5,796,990) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,709,350 (3,796,270 - 5,814,670) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,677,050 (3,775,130 - 5,778,830) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,598,950 (3,717,030 - 5,692,650) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,484,290 (3,626,480 - 5,557,990) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,028,680 (3,237,380 - 4,989,090) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,653,510 (2,923,220 - 4,526,480) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,714,410 (2,968,620 - 4,593,600) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,801,920 (3,024,380 - 4,710,050) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,774,440 (2,999,760 - 4,679,890) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Women of childbearing age (15–49 years)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 2,219,000 (1,659,000 - 2,316,000) | 2019 | Modelled | Dugan et al., 2021 |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 7.87 (5.69 - 11) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 10.08 (6.43 - 15.21) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.02 (6.50 - 14.94) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.92 (6.73 - 14.42) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.99 (6.61 - 14.73) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.96 (7.09 - 13.93) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.91 (6.88 - 14.08) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.89 (7.14 - 13.47) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.78 (7.28 - 13.06) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.6 (7.17 - 12.91) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.48 (7.18 - 12.53) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.45 (7.22 - 12.36) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.27 (7.18 - 11.99) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.38 (7.23 - 12.11) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.11 (7.08 - 11.56) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.96 (7 - 11.61) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.82 (6.81 - 11.27) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.7 (6.68 - 11.15) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.53 (6.63 - 11.24) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.59 (6.60 - 11.07) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.4 (6.24 - 11.02) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.47 (6.35 - 11.08) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.31 (6.19 - 10.92) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.25 (6.07 - 11.03) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.27 (5.99 - 11.13) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.24 (6.09 - 11.11) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.16 (5.96 - 11.03) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.13 (6 - 10.89) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.15 (5.94 - 10.98) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.03 (5.78 - 10.91) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.87 (5.69 - 10.96) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 12,122 | 2016 | Modelled | WHO |
| 17,644 (12,752 - 24,554) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17,644 (12,752 - 24,554) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 17,606 (12,684 - 23,927) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17,502 (12,769 - 23,584) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17,094 (12,617 - 22,890) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16,793 (12,256 - 22,683) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16,569 (12,252 - 22,347) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 16,252 (11,766 - 21,883) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,845 (11,655 - 21,185) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,579 (11,600 - 20,467) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,371 (11,414 - 20,171) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15,122 (11,335 - 19,790) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,862 (11,539 - 19,580) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,579 (11,208 - 18,799) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,395 (11,063 - 18,452) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,232 (10,984 - 18,192) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14,098 (11,009 - 18,265) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,975 (10,856 - 17,735) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,861 (10,739 - 17,926) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,671 (10,545 - 17,661) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,440 (10,269 - 17,568) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13,148 (9,955 - 17,386) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,993 (9,708 - 17,473) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,925 (9,625 - 17,267) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,775 (9,227 - 17,400) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,572 (8,953 - 17,585) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12,227 (8,487 - 17,376) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,973 (8,126 - 17,396) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,786 (7,806 - 17,382) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,566 (7,503 - 17,243) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11,379 (7,256 - 17,165) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Number of persons treated for HCV
Cumulative number of persons treated for HCV
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 18 (16 - 21) | 2015 | Survey/reported | Larney et al, 2017 |
Number of 28-pill count bottles exported from Indian manufacturers (SOF-based regimens)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 73,386 | 2016 | Survey/reported | CHAI HCV Market Report |
| 100,002 | 2017 | Survey/reported | CHAI HCV Market Report |
| 104,504 | 2018 | Survey/reported | CHAI HCV Market Report |
| 68,661 | 2019 | Survey/reported | CHAI HCV Market Report |
Showing out of
Show more
Percent of PWID accessing OST
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0 | 2015 | Survey/reported | NACP, 2015. |
Price of HCV cure (Lowest average FOB price for 3 months of pangenotypic regimens)
National
Download| Value (US $) | Year | Type | Source |
|---|---|---|---|
| 231 | 2016 | Survey/reported | CHAI HCV Market Report |
| 84 | 2017 | Survey/reported | CHAI HCV Market Report |
| 60 | 2018 | Survey/reported | CHAI HCV Market Report |
| 75 | 2019 | Survey/reported | CHAI HCV Market Report |
Showing out of
Show more
Price of HCV cure (Average price in public sector for 3 months of DAAs)
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Eligible for HBV generic medicines
Year of birth dose introduction
2016
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)
Overview
HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030
Hepatitis related deaths (national)
Modelled
HBV
16,208
2019
(11,878 - 21,656)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
17,644
2019
(12,752 - 24,554)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.91
(%)
2020, latest modelled
(0.79 - 1.04(%))
WHO
Birth dose vaccination coverage (national)
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines
